SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ — Iinnofashion is accelerating its global beauty market strategy, following its participation in the 2025 Seoul Beauty Expo and its recent appearance at the Japan Cosmetic Exhibition held in Osaka this October.

The company’s flagship product, the All-in-One Toner Mask Bubble Booster, is gaining recognition as an innovative solution aligned with the rising trend of bubble-type beauty products. Unlike conventional liquid toners, it contains CICA ingredients and delivers multiple effects—soothing, brightening, nourishing, and mask-pack benefits—all in a single formula. Its ability to provide a comprehensive skincare routine with one product has made it especially appealing to busy modern consumers.

In Russia, Iinnofashion ‘s brand IINNO PURE COSME has already received strong customer response through its broadcast on the Leomax home shopping channel. In China, the company is currently in discussions for marketing collaborations through Douyin live commerce. Additionally, Iinnofashion is preparing to open a shop-in-shop targeting Chinese tourists at Jeju Dongmun Market this November, further expanding its global distribution network across both online and offline channels.

“We aim to strengthen our presence in key markets including Japan, Russia, and China, while also pursuing entry into Southeast Asia,” the company stated. “Our goal is to establish ourselves as a leading global brand representing K-beauty.”

SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ — SURFIRAN CO LTD has announced a strategic collaboration with Master Artisan Insuk Jung, a leading figure in Korean traditional fermentation, to co-develop innovative saffron-based premium products.

The partnership aims to make saffron more familiar to Korean consumers by combining Master Jung’s fermentation expertise with SURFIRAN CO LTD’s specialization in top-quality saffron. Master Jung directly oversaw the entire production process, ensuring balanced fermentation and premium quality.

Industry observers note that this collaboration represents a rare fusion of world-class saffron and Korean fermentation craftsmanship—an effort expected to spark new trends in the domestic gourmet food sector.

A SURFIRAN CO LTD representative said, “Master Jung’s involvement elevated the flavor profile and authenticity of our products. We plan to continue developing items that blend saffron with Korean culinary culture.”

• Integrates ToolGen’s best-in-class CRISPR-Cas9 platform with GenEditBio’s industry-leading lipid nanoparticle (LNP) delivery technology
• Pursues a “once-and-done” treatment paradigm for diseases with high unmet medical needs

SEOUL, South Korea and HONG KONG, Nov. 24, 2025 /PRNewswire/ — GenEditBio Limited (“GenEditBio”), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, including lipid nanoparticle (LNP)-based delivery systems, announced today that it has entered into a strategic cross-license agreement with ToolGen Inc., a leading genome editing company based in Korea. Through this agreement, the companies will jointly advance the development of next-generation in vivo genome-editing therapeutics.

This collaboration brings together two essential and highly complementary technologies—ToolGen’s best-in-class CRISPR-Cas9 genome editing platform and GenEditBio’s industry-leading LNP delivery system. Together, these platforms enable a transformative approach to genome-editing therapeutics, aiming for a single-administration (“once-and-done”) treatment for diseases with significant unmet clinical needs.

The success of in vivo genome editing requires not only high-precision genome editing tools such as CRISPR-Cas9, but also a delivery system that ensures safe and efficient targeting of therapeutic cargo to the desired tissues. This collaboration leverages the respective strengths of both parties to generate strong synergies across the development pathway.

GenEditBio is developing GEB-200, an investigational in vivo genome-editing therapy targeting atherosclerotic cardiovascular disease (ASCVD). The company possesses proprietary LNP and other key delivery technologies optimized for the safe and efficient in vivo delivery of genome-editing agents such as CRISPR-Cas9. GEB-200 is designed to permanently lower plasma levels of lipoprotein(a), or Lp(a), a genetic risk factor affecting approximately 20% of the global population. The program has gained attention as a potential once-and-done alternative to existing chronic therapies in the cardiovascular field.

ToolGen and GenEditBio have been closely collaborating from the early development stages of GEB-200, combining their respective strengths to drive the program forward. The companies recently completed a successful proof-of-concept study in non-human primates (NHPs), which demonstrated effective target gene modulation and a favorable safety profile—marking a key milestone toward IND submission.

Looking ahead, ToolGen and GenEditBio plan to accelerate the regulatory path for GEB-200 by leveraging their integrated platform capabilities and to jointly explore global licensing opportunities under mutually agreed terms.

GenEditBio Co-founder and Chairman Prof. Zongli Zheng commented:

“GenEditBio and ToolGen share the same philosophy that ‘Together, We Are Stronger’ and a common goal of bringing safe and effective genome-editing therapies to patients with unmet medical needs. We are excited to enter this cross-license agreement with ToolGen to accelerate the development of GEB-200 beyond preclinical stage. The collaboration attests to our high-throughput LNP barcoding system that is highly predictive in clinical translation and ToolGen’s advanced CRISPR-Cas9 genome-editing technology.”

ToolGen CEO Dr. Jong Sang Ryu commented:

“Investor interest in gene-editing therapies targeting cardiovascular diseases is growing rapidly. Eli Lilly’s recent acquisition of Verve Therapeutics—whose pipeline includes an Lp(a)-targeted gene-editing program—for $1 billion upfront and up to $300 million in contingent value rights clearly reflects this trend. Through our strategic collaboration with GenEditBio, we aim to deliver a breakthrough in gene-editing treatment by combining ToolGen’s CRISPR expertise with GenEditBio’s advanced delivery technology, ultimately bringing transformative, once-and-done therapeutic options to patients worldwide.”

About ToolGen

ToolGen Inc. is a leading biotechnology company that leverages its foundational patent portfolio for CRISPR-Cas9 to drive research and business development in three core areas: IP Monetization, Therapeutics, and Crop Science. As a pivotal gene-editing technology, CRISPR-Cas9 enables the precise and selective modification of genetic information within cells, making it an extensively applied tool across the life sciences. The strength and value of ToolGen’s foundational CRISPR-Cas9 patents are demonstrated by their registration in 10 key jurisdictions, including the United States, Europe, China, Australia, and Japan. Furthermore, the technology’s competitive edge has been validated through out-licensing agreements with global industry leaders such as Monsanto and Thermo Fisher Scientific.

About GenEditBio

Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a clinical-stage gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed “DNA surgery”) with high safety profile, unmatched precision, and affordable access for genetic diseases with unmet needs. The Company’s core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing lipid nanoparticle (LNP) and engineered protein delivery vehicle (PDV). We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston. GenEditBio is financially backed by top-tier life science investors, including Qiming Venture Partners, Fangyuan Capital, Center Biotherapeutics, Lumosa Therapeutics, HKSTP Venture Fund, and others. For more information, please visit www.geneditbio.com.

ToolGen
Investors Contact
Ig.lee@toolgen.com

GenEditBio
Media Contact
geb.media@geneditbio.com

Investors Contact
bd@geneditbio.com

• WORLD HYDROGEN EXPO 2025 will take place from Wednesday, December 4 to Sunday, December 7 at KINTEX.
• The event will showcase a full program, including H2 MEET, the world’s largest hydrogen exhibition, and the WHE 2025 Conference featuring global industry leaders.
• The scale and stature of the event will be given greater international weight through coordination with the Hydrogen Council CEO Summit, a global coalition of hydrogen companies.

SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ — The WORLD HYDROGEN EXPO 2025 (“WHE 2025”), set to become the world’s largest hydrogen industry exhibition, will be held for four days from Wednesday, December 4, to Sunday, December 7, at KINTEX in Seoul, Korea.

The WHE 2025 Organizing Committee (the “Committee”) announced that it is integrating South Korea’s leading hydrogen industry exhibition, H2 MEET, held annually since 2020, with the nation’s largest hydrogen international conference, which took place last year on Hydrogen Day (November 2), under the unified global name World Hydrogen Expo, beginning this year.

• Co-Chairmen of the Organizing Committee: Kang Nam-hoon, Chairman of the Korea Automobile & Mobility Association, and Kim Jae-hong, Chairman of the Korea Hydrogen Alliance.

As WHE 2025 launches as an integrated platform encompassing both an exhibition and a conference, the Committee aims to establish the foundation for South Korea’s emergence as a global hydrogen hub by providing a forum where global hydrogen industry companies and key leaders gather to share and discuss the importance of developing the hydrogen economy and strengthening global cooperation.

H2 MEET, which will be held from December 4 to 7 (four days) in KINTEX Exhibition Center 2 (Halls 7 and 8), is the flagship exhibition for the hydrogen industry, featuring companies, institutions, and organizations across the hydrogen production, storage/transport, and utilization sectors, and has been held annually since its first edition in 2020. Last year, the event was recognized as a world-class exhibition, drawing more than 320 companies from 24 countries and over 30,000 visitors. This year, the exhibition will extend through the weekend, giving general visitors a rare opportunity to experience hydrogen technologies firsthand.

From December 4 to 5 (two days), the newly reorganized WHE 2025 Conference, which updates the existing hydrogen conference, will be conducted across three distinct sessions.

The Leadership Address session will feature high-level government officials from key countries, including South Korea, Japan, Germany, the United States, Australia, and Malaysia, who will share global policy priorities as they present their national strategies for the transition to clean hydrogen.

In the Hydrogen Deep Dive session, world-leading companies and industry experts will deliver in-depth presentations and discussions on key issues such as the hydrogen supply chain, technology commercialization, international standards and outline practical solutions.

The Country Day session will consist of technical seminars hosted by the national pavilions of participating countries, focusing on each country’s hydrogen industry policies and technology trends.

In addition to the exhibition and conference, several side events will be held concurrently during the event period.

The Global Partnership Meeting for the Hydrogen Industry (December 4–7), co-organized by the Committee and KOTRA, will support business matching between domestic hydrogen companies and global buyers to facilitate the international expansion of South Korean firms during the event.

The 6th Korea–Germany Hydrogen Conference (December 3) is expected to feature technical exchange between experts from both countries across five major sectors: hydrogen policy, production, storage, utilization, and safety.

Furthermore, the 8th General Assembly (December 5) of the Global Hydrogen Industrial Associations Alliance (GHIAA*), involving hydrogen organizations from 26 countries, is expected to serve as an important milestone in strengthening South Korea’s role as a hub for global hydrogen cooperation.

• GHIAA: The Global Hydrogen Industrial Associations Alliance (GHIAA) is an international coalition founded to promote the transition to a clean hydrogen economy and global cooperation and currently includes 26 member countries.

The event is also being scheduled in December to align with the Hydrogen Council CEO Summit (December 2–4), where leaders of global hydrogen companies will convene, and the participating hydrogen company leaders will engage with domestic companies and organizations across the event lineup, including the opening ceremony, exhibition, conference, and business meetings.

• Hydrogen Council: A consortium composed of more than 150 global hydrogen companies.

Kang Nam-hoon, Chairman of the WHE Organizing Committee, stated, “As we prepare for this event under the new name World Hydrogen Expo, aiming for it to become the world’s premier and largest hydrogen exhibition, we are working to attract top-tier speakers, senior government officials from around the world, and leading global hydrogen companies,” adding, “We will strive for a successful event that can offer a clear overview of global hydrogen industry trends and contribute to strengthening the foundation for global cooperation across the entire industry.” More detailed information is available on the official website (www.world-hydrogen-expo.com).

– Pioneering high-speed connectivity and intelligent management for next-generation workspaces –

SHANGHAI, Nov. 24, 2025 /PRNewswire/ — Universal Scientific Industrial (Shanghai) Co., Ltd. (USI) today announced the successful collaboration with a world-renowned brand customer to develop and mass-produce the latest generation of Thunderbolt™ 5 Smart Dock. The solution embodies USI’s commitment to innovation, sustainability, and close co-creation with global technology leaders, further solidifying its role as a trusted development and manufacturing partner in the premium PC and peripheral ecosystem.

Designed for modern hybrid work and creative environments, the Smart Dock delivers the next leap in bandwidth, power delivery, and intelligent management, empowering users to seamlessly extend their laptops into full-featured desktop workstations. The Smart Dock integrates Intel’s latest Thunderbolt™ 5 technology, offering up to 120 Gbps of bandwidth—three times faster than the previous generation—supporting multiple displays, including up to three 8K 60Hz or dual 4K high-refresh-rate monitors. It features cross-OS compatibility, PD 3.1 fast charging up to 180 W, and arc-protection design, providing both performance and reliability demanded by business professionals, creators, and gamers.

According to Grand View Research, the global docking station market is projected to grow at a compound annual growth rate (CAGR) of 6.1 % from 2023 to 2030. This growth reflects the acceleration of remote and hybrid work, the increasing need for multi-display productivity setups, and the rise of AI-enhanced creative workflows. With Thunderbolt™ 5 delivering triple bandwidth and broader device compatibility, demand for next-generation smart docks combining ultra-high-speed data transfer, intelligent device management, and sustainability is rapidly expanding across enterprise, creative, and gaming sectors.

As the Intel® Evo™-certified Thunderbolt™ 5 dock, this Smart Dock ensures seamless compatibility and optimized performance with Evo laptops. It also integrates a Wi-Fi IoT module supporting cloud-based device management, enabling IT administrators to remotely monitor, update, configure, and diagnose devices through a web browser—delivering exceptional efficiency and flexibility in enterprise deployment.

“This project not only reinforces USI’s leadership in the premium docking station segment but also highlights our comprehensive strengths in high-speed interface design, power delivery, software development, and system integration,” said Susan Shieh, Director of Port Replicator Product Center at USI. “We will continue investing in innovation and quality to deliver exceptional product value and remain a trusted partner in design and manufacturing.”

About USI (SSE: 601231)

USI, Universal Scientific Industrial (Shanghai) Co., Ltd., is a global leader in electronic design and manufacturing as well as a leader in the field of SiP (System-in-Package) technology. Our production and service locations span four continents: Asia, Europe, the Americas, and Africa, offering customer diversified electronic products with D(MS)² services: Design, Manufacturing, Miniaturization, Industrial software, and hardware Solutions, as well as material procurement, logistics and maintenance Services. USI is a subsidiary of ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX). To learn more, please visit www.usiglobal.com and engage with us on LinkedIn and YouTube.